ECSP099788A - Preparación farmacéutica acuosa - Google Patents

Preparación farmacéutica acuosa

Info

Publication number
ECSP099788A
ECSP099788A EC2009009788A ECSP099788A ECSP099788A EC SP099788 A ECSP099788 A EC SP099788A EC 2009009788 A EC2009009788 A EC 2009009788A EC SP099788 A ECSP099788 A EC SP099788A EC SP099788 A ECSP099788 A EC SP099788A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical preparation
water pharmaceutical
preparation
aqueous pharmaceutical
water
Prior art date
Application number
EC2009009788A
Other languages
English (en)
Inventor
Holger Bauer
Norbert Rasenack
Kerstin Ammer
Bianka Kemmerer
Kirstin Heil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP099788A publication Critical patent/ECSP099788A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una una preparación farmacéutica acuosa que contiene 1-(2-dimetilamino-etil)-3-((2R,4aS,5R,10bS)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2H-pirano[3,2-c]quinolin-2-ilmetil)-urea como principio activo, una preparación farmacéutica líquida que es apropiada para la preparación de la preparación farmacéutica acuosa, así como a procedimientos para producir las preparaciones.
EC2009009788A 2007-05-10 2009-12-08 Preparación farmacéutica acuosa ECSP099788A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007021862A DE102007021862A1 (de) 2007-05-10 2007-05-10 Wässrige pharmazeutische Zubereitung

Publications (1)

Publication Number Publication Date
ECSP099788A true ECSP099788A (es) 2010-01-29

Family

ID=39537491

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009788A ECSP099788A (es) 2007-05-10 2009-12-08 Preparación farmacéutica acuosa

Country Status (20)

Country Link
US (1) US20100210681A1 (es)
EP (1) EP2142169B1 (es)
JP (1) JP2010526783A (es)
KR (1) KR20100029758A (es)
CN (1) CN101677941A (es)
AR (1) AR066504A1 (es)
AT (1) ATE530164T1 (es)
AU (1) AU2008250717A1 (es)
BR (1) BRPI0811431A2 (es)
CA (1) CA2686765A1 (es)
CL (1) CL2008001384A1 (es)
CO (1) CO6220901A2 (es)
DE (1) DE102007021862A1 (es)
EA (1) EA200901498A1 (es)
EC (1) ECSP099788A (es)
IL (1) IL201912A0 (es)
MX (1) MX2009012035A (es)
PE (1) PE20090246A1 (es)
TW (1) TW200911252A (es)
WO (1) WO2008138459A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
KR102126727B1 (ko) 2018-03-29 2020-07-07 이혜영 자동차 표면 광택방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE507220T1 (de) * 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
NZ574236A (en) * 2006-06-19 2010-11-26 Merck Patent Gmbh Processes for preparing pyranoquinolines and crystal forms thereof

Also Published As

Publication number Publication date
AR066504A1 (es) 2009-08-26
CL2008001384A1 (es) 2009-09-25
IL201912A0 (en) 2010-06-16
DE102007021862A1 (de) 2008-11-13
CO6220901A2 (es) 2010-11-19
AU2008250717A1 (en) 2008-11-20
PE20090246A1 (es) 2009-03-19
ATE530164T1 (de) 2011-11-15
US20100210681A1 (en) 2010-08-19
WO2008138459A2 (de) 2008-11-20
KR20100029758A (ko) 2010-03-17
JP2010526783A (ja) 2010-08-05
EP2142169A2 (de) 2010-01-13
BRPI0811431A2 (pt) 2015-06-16
EP2142169B1 (de) 2011-10-26
CA2686765A1 (en) 2008-11-20
TW200911252A (en) 2009-03-16
WO2008138459A3 (de) 2009-06-04
MX2009012035A (es) 2009-11-18
EA200901498A1 (ru) 2010-04-30
CN101677941A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
ECSP12011880A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
UA108641C2 (uk) Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
NZ628398A (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
UY33075A (es) Derivados de ciclohexano y usos de los mismos
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
ECSP099716A (es) Extrudidos con enmascaramiento del sabor mejorado
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
ECSP099788A (es) Preparación farmacéutica acuosa
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
ECSP088647A (es) Nueva sal de citrato de un derivado de indol y su uso farmacéutico
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
BR112019006937A2 (pt) Composição farmacêutica, composto, forma cristalina do composto, agentes para reduzir sulfato de indoxila no sangue, para prevenir ou tratar uma doença causada por um aumento de sulfato de indoxila no sangue, para retardar a transição para terapia desubstituição renal e para suprimir o agravamento da função renal remanescente em um paciente após transição para terapia de substituição renal, uso do composto, e, métodos para reduzir sulfato de indoxila no sangue e para prevenir ou tratar uma doença
UY33073A (es) Nuevos derivados del tipo hexahidrociclopenta [ b]pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
GT200800178A (es) Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina
EA201401265A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и оксикам
EA201401269A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано[3,4,b]индол]-4-амин и антидепрессанты
CU20120091A7 (es) Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY33074A (es) Nuevos derivados de azabiciclo[3.2.0]hept-6-ilo, su procedimiento de preparación y las composiciones farmacéuticas que los contienen